Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | CPN1 | P15169 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14646583 | 0.82 | HRH3 (0.40) | EEDEPHX1CPN1CPB2HRH4 | |
| SCHEMBL9917291 | 0.82 | HRH3 (0.40) | EEDEPHX1CPN1CPB2HRH4 | |
| SCHEMBL14071147 | 0.82 | HRH3 (0.40) | EEDEPHX1CPN1CPB2HRH4 | |
| SCHEMBL21214343 | 0.81 | PLG (0.33) | EEDEPHX1HRH4HRH3 | |
| SCHEMBL11915915 | 0.76 | HRH3 (0.35) | EEDEPHX1CPN1CPB2HRH4 | |
| SCHEMBL20668640 | 0.75 | HRH3 (0.36) | EEDEPHX1CPN1CPB2HRH4 | |
| SCHEMBL20259719 | 0.74 | HRH3 (0.35) | EEDEPHX1CPN1CPB2HRH4 | |
| SCHEMBL25645276 | 0.73 | THRA (0.31) | — | |
| SCHEMBL24967876 | 0.72 | CYP2D6 (0.33) | — | |
| SCHEMBL20259728 | 0.72 | CPN1 (0.30) | CPN1CPB2HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | EED 75/4885EPHX1 2679/4885CPN1 3907/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | EED 75/4885EPHX1 2679/4885CPN1 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.